Trial results for a study investigating a multi-level intervention to empower lung cancer screening uptake were posted on ClinicalTrials.gov on 2026-02-03, showing that an order for low-dose computed tomography (LDCT) was placed for 50 participants.
Background
Lung cancer remains the leading cause of cancer-related mortality globally. Lung cancer screening (LCS) using low-dose computed tomography (LDCT) has been shown to decrease the mortality rate of lung cancer by 20%. Despite this proven benefit, many eligible patients do not undergo screening, which prevents early detection of the disease. Interventions aimed at improving screening uptake are crucial to ensure more patients benefit from early diagnosis and treatment.
Trial design
This completed study, identified as Phase NA, enrolled 79 participants with Lung Cancer. The trial aimed to test the effect of a multi-level intervention on ordering LDCT within 6 months after patient enrollment. The intervention included primary care provider notifications of patients' LCS eligibility and patient education. The study did not list specific primary outcomes in the provided data.
Key results
The trial results focused on several key measurements related to lung cancer screening uptake and patient/provider perceptions:
- For the group identified as "Patient Participants," the number of participants for whom an Order of LDCT was placed was 50.
- For the group identified as "Empower LCS," the number of participants who had Receipt of LDCT was 17.
- Also for the "Empower LCS" group, the number of participants who had an LCS Discussion was 43.
- Regarding patient perceptions within the "Empower LCS" group, the Perceived Benefit of Lung Cancer Screening had a mean score of 24.7 with a standard deviation of 4.7 on a scale.
- The Perceived Barriers to Lung Cancer Screening in the "Empower LCS" group had a mean score of 37.5 with a standard deviation of 15.6 on a scale.
- Knowledge About Lung Cancer and Screening for the "Empower LCS" group showed a mean score of 2.7 with a standard deviation of 1.6 on a scale.
- For "Primary Care Providers," the Providers' Perceived Barriers to Lung Cancer Screening had a mean score of 24.1 with a standard deviation of 4.2 on a scale.
What this means
The posted results indicate that the multi-level intervention led to LDCT orders for 50 participants and actual receipt of LDCT for 17 participants, alongside 43 participants engaging in an LCS discussion. These findings suggest that such interventions can facilitate the initial steps towards lung cancer screening. The reported scores on perceived benefits, barriers, and knowledge provide insights into the psychological and educational impacts of the intervention, highlighting areas where patient understanding and readiness for screening may have been influenced. Addressing perceived barriers and enhancing knowledge are critical components for improving overall screening rates for lung cancer.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06000683, titled "Empowering Patients' Lung Cancer Screening Uptake", were posted on 2026-02-03 on clinicaltrials.gov.